Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2014

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #1485

    Tak i lige måde:-)

    1 Reply Last reply
    0
    • celsiusC Offline
      celsiusC Offline
      celsius
      wrote on sidst redigeret af
      #1486

      Så kommer afgørelsen inden for en time gætter jeg på

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #1487

        Mon ikke det først er i morgen?

        1 Reply Last reply
        0
        • JørgenVarnæsJ Offline
          JørgenVarnæsJ Offline
          JørgenVarnæs
          wrote on sidst redigeret af
          #1488

          det er også mit bud, men vi er helt oppe imod målstregen lige nu - så den kan vel falde nårsomhelst!!!

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JSEH
            wrote on sidst redigeret af
            #1489

            Genmab A/S (GMXAY) -Other OTC
            17.67 Up 0.65(3.82%) 12:24PM EDT

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JSEH
              wrote on sidst redigeret af
              #1490

              Volume: 1,177

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #1491

                Comparison of CDC activity using rituximab and ofatumumab revealed that the cytotoxic activity of ofatumumab was significantly higher than that of rituximab. http://onlinelibrary.wiley.com/doi/10.1111/bjh.12857/full

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #1492

                  she was receiving ofatumumab, a humanized anti-CD20 monoclonal antibody approved by the Food and Drug Administration for the treatment of multidrug-resistant CLL, with efficacy against rituximab-resistant B-cell cancers.4 Therapy with ofatumumab produced a dramatic response in the patient's renal status

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #1493

                    Just a moment...

                    favicon

                    (www.nejm.org)

                    1 Reply Last reply
                    0
                    • G Offline
                      G Offline
                      gentogen
                      wrote on sidst redigeret af
                      #1494

                      Recent studies show that ofatumumab can replace rituximab in the fludarabine/cyclophosphamide/rituximab regimen for patients with CLL.

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #1495

                        301 Moved Permanently

                        favicon

                        (www.theoncologynurse.com)

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #1496

                          A phase 2 trial confirmed comparable high activity and safety of the O-FC (ofatumumab/fludarabine/cyclophosphamide) regimen as frontline treatment of previously untreated CLL. Investigators are moving forward with this regimen using the 1000-mg dose of ofatumumab.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #1497

                            a combination of ofatumumab plus lenalidomide has been tested extensively at MD Anderson Cancer Center and shown to be extremely effective. Studies show an overall response rate of 68 percent and a complete response rate of 24 percent.

                            1 Reply Last reply
                            0
                            • BudweisB Offline
                              BudweisB Offline
                              Budweis
                              wrote on sidst redigeret af
                              #1498

                              Det ser ikke så tosset ud

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #1499

                                Just a moment...

                                favicon

                                (journals.lww.com)

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #1500

                                  favicon

                                  (abstracts.hematologylibrary.org)

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #1501

                                    24% CR i relapsed CLL i 2012. Utroligt, at GSK er SÅ passive

                                    1 Reply Last reply
                                    0
                                    • JørgenVarnæsJ Offline
                                      JørgenVarnæsJ Offline
                                      JørgenVarnæs
                                      wrote on sidst redigeret af
                                      #1502

                                      rigtig flot luk i US med index oppe 2,5% - men mon ikke der er andet, der sætter dagsordenen på tirsdag....

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #1503

                                        Betyder det, at appelsinerne atter forlader FF´s turban?

                                        1 Reply Last reply
                                        0
                                        • JørgenVarnæsJ Offline
                                          JørgenVarnæsJ Offline
                                          JørgenVarnæs
                                          wrote on sidst redigeret af
                                          #1504

                                          det er vist kun i hans eget hoved, at der har været appelsiner i hans turban

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger